NASA Awards $3.24M for Nanobioreactor R&D to Aspera Biomedicines

Contract Overview

Contract Amount: $3,240,000 ($3.2M)

Contractor: Aspera Biomedicines, Inc.

Awarding Agency: National Aeronautics and Space Administration

Start Date: 2024-12-05

End Date: 2027-12-31

Contract Duration: 1,121 days

Daily Burn Rate: $2.9K/day

Competition Type: COMPETED UNDER SAP

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: R&D

Official Description: RESEARCH AND DEVELOPMENT FOR IN-SPACE PRODUCTION CONCEPTS OF NANOBIOREACTOR MODELS. THIS WAS AWARDED OFF OF THE NASA RESEARCH ANNOUNCEMENT NNJ13ZBG001N. NOTE THAT "BASIC RESEARCH" IS NOT A SELECTABLE SOLICITATION TYPE FOR PURCHASE ORDERS IN FPDS.

Place of Performance

Location: LA JOLLA, SAN DIEGO County, CALIFORNIA, 92037

State: California Government Spending

Plain-Language Summary

National Aeronautics and Space Administration obligated $3.2 million to ASPERA BIOMEDICINES, INC. for work described as: RESEARCH AND DEVELOPMENT FOR IN-SPACE PRODUCTION CONCEPTS OF NANOBIOREACTOR MODELS. THIS WAS AWARDED OFF OF THE NASA RESEARCH ANNOUNCEMENT NNJ13ZBG001N. NOTE THAT "BASIC RESEARCH" IS NOT A SELECTABLE SOLICITATION TYPE FOR PURCHASE ORDERS IN FPDS. Key points: 1. Focuses on advanced biotechnology R&D for space applications. 2. Awarded via NASA Research Announcement, indicating a specific call for proposals. 3. Potential for significant advancements in in-space manufacturing and life support. 4. Limited direct competition data available, but the award mechanism suggests a focused search.

Value Assessment

Rating: good

The $3.24M award for a 3-year R&D project appears reasonable given the specialized nature of nanobioreactor development for space. Benchmarking is difficult without more specific contract details, but the price seems aligned with advanced research initiatives.

Cost Per Unit: N/A

Competition Analysis

Competition Level: limited

The contract was competed under SAP (Simplified Acquisition Procedures), suggesting a competitive process, but the specific solicitation type (NASA Research Announcement) implies a targeted approach to a specific research need rather than broad market competition.

Taxpayer Impact: Taxpayer funds are supporting cutting-edge research with potential long-term benefits for space exploration and technology.

Public Impact

Advancing biotechnology capabilities for future space missions. Potential for new manufacturing techniques in orbit. Supports scientific innovation and the growth of the space technology sector.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

  • Limited public data on the competitive landscape.
  • Specific R&D focus may limit immediate commercial applicability.

Positive Signals

  • Supports critical NASA research objectives.
  • Invests in advanced technological development.
  • Long-term project duration allows for thorough research.

Sector Analysis

This contract falls within the Research and Development in Biotechnology sector, specifically focusing on advanced nanobioreactor models for in-space production. Spending in this niche area is driven by government space exploration initiatives and is characterized by high innovation and specialized expertise.

Small Business Impact

The awardee, Aspera Biomedicines, Inc., is not indicated as a small business. Further analysis would be needed to determine if small business participation was sought or achieved through subcontracting.

Oversight & Accountability

Awarded under a NASA Research Announcement, suggesting a structured process. Oversight will be critical to ensure milestones are met and funds are used effectively for the intended R&D objectives.

Related Government Programs

  • Research and Development in Biotechnology (except Nanobiotechnology)
  • National Aeronautics and Space Administration Contracting
  • National Aeronautics and Space Administration Programs

Risk Flags

  • Potential for technology to not mature as expected.
  • Limited visibility into the full competitive process.
  • High R&D costs with uncertain return on investment.
  • Dependence on a single awardee for critical research.

Tags

research-and-development-in-biotechnolog, national-aeronautics-and-space-administr, ca, purchase-order, 1m-plus

Frequently Asked Questions

What is this federal contract paying for?

National Aeronautics and Space Administration awarded $3.2 million to ASPERA BIOMEDICINES, INC.. RESEARCH AND DEVELOPMENT FOR IN-SPACE PRODUCTION CONCEPTS OF NANOBIOREACTOR MODELS. THIS WAS AWARDED OFF OF THE NASA RESEARCH ANNOUNCEMENT NNJ13ZBG001N. NOTE THAT "BASIC RESEARCH" IS NOT A SELECTABLE SOLICITATION TYPE FOR PURCHASE ORDERS IN FPDS.

Who is the contractor on this award?

The obligated recipient is ASPERA BIOMEDICINES, INC..

Which agency awarded this contract?

Awarding agency: National Aeronautics and Space Administration (National Aeronautics and Space Administration).

What is the total obligated amount?

The obligated amount is $3.2 million.

What is the period of performance?

Start: 2024-12-05. End: 2027-12-31.

What is the specific technological advancement expected from these nanobioreactor models?

The nanobioreactor models are expected to enable the production of biological materials, such as pharmaceuticals or nutrients, in the microgravity environment of space. This could revolutionize long-duration space missions by reducing reliance on Earth-based resupply and supporting closed-loop life support systems.

What are the primary risks associated with this R&D project?

Key risks include the inherent scientific and technical challenges of developing novel bioreactor technology for space, potential delays in research progress, and the possibility that the developed technology may not meet the stringent requirements for spaceflight. Ensuring long-term viability and scalability of the nanobioreactor models also presents a significant risk.

How does this investment contribute to NASA's broader mission objectives?

This investment directly supports NASA's goals of enabling long-duration human spaceflight and establishing a sustainable presence beyond Earth. By developing capabilities for in-space production, it reduces logistical burdens and enhances crew autonomy, crucial for missions to the Moon, Mars, and beyond.

Industry Classification

NAICS: Professional, Scientific, and Technical ServicesScientific Research and Development ServicesResearch and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENTN – Health R&D Services

Competition & Pricing

Extent Competed: COMPETED UNDER SAP

Solicitation Procedures: SIMPLIFIED ACQUISITION

Solicitation ID: NNJ13ZBG001N

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 7510 HILLSIDE DR, LA JOLLA, CA, 92037

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $4,000,000

Exercised Options: $4,000,000

Current Obligation: $3,240,000

Actual Outlays: $1,440,000

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Timeline

Start Date: 2024-12-05

Current End Date: 2027-12-31

Potential End Date: 2027-12-31 00:00:00

Last Modified: 2026-03-17

Other National Aeronautics and Space Administration Contracts

View all National Aeronautics and Space Administration contracts →

Explore Related Government Spending